Mastermyne enters FY27 with $834 million order book and bigger growth ambitions

Mastermyne Group Limited (ASX:MYE) has set FY27 revenue guidance of $305 million to $320 million and underlying EBITDA guidance of $28.5 million to $31.5 million after new contracts more than doubled its order book to approximately $834 million. The mining services group is also assessing expansion into surface mining and other adjacent markets.

  • FY27 revenue guidance of $305 million to $320 million
  • Underlying EBITDA guidance of $28.5 million to $31.5 million
  • Order book rises to approximately $834 million after Dendrobium and Tahmoor wins
  • Workforce expected to exceed 1,000 by January 2027
  • Strategic review examining surface mining expansion and acquisitions
An image related to Mastermyne Group Limited A photo of the logo for Mastermyne Add us as a preferred source on Google
Image © middle. Logo © respective owner.

New contracts underpin higher FY27 earnings target

Mastermyne is entering FY27 with a larger order book, stronger cash position and a more ambitious earnings target. The underground coal services provider expects revenue of $305 million to $320 million and underlying EBITDA of $28.5 million to $31.5 million, representing increases of 26% to 35% and 40% to 55% respectively on FY26.

The guidance arrives after the order book expanded from $432 million at 30 June to approximately $834 million at 31 October. About $366 million represents current-term work, including roughly $140 million linked to FY27, while the balance includes extension opportunities. The company said the guidance assumes no material change in operating or market conditions.

Dendrobium and Tahmoor reshape the contract base

The step-up is being driven chiefly by two New South Wales mining services awards. At GM3’s Dendrobium mine, Mastermyne has an initial two-year contract worth approximately $85 million in estimated gross revenue, with two further two-year options that could take the total to about $255 million. Mobilisation is essentially complete and more than 140 roles have been added.

At Tahmoor, where a consortium comprising M Group and GEAR acquired the mine and GM3 will operate it, Mastermyne has secured an initial two-year contract worth approximately $80 million. Two extension options could lift the estimated gross revenue to approximately $240 million over six years, with mobilisation expected to be complete by January 2027. The Tahmoor award had previously been reported as a Tahmoor mining contract, while the Dendrobium deal followed the earlier Dendrobium services contract.

Those figures are gross revenue estimates rather than guaranteed outcomes, and the extension options are not committed work. Even so, the contracts give Mastermyne a larger presence across GM3’s Appin, Dendrobium and Tahmoor operations. A separate three-year strata consolidation agreement covering Appin and Dendrobium, with a two-year extension option, is also now operational.

FY26 growth provides the earnings base

Mastermyne’s FY26 result gives the new guidance a stronger starting point. Revenue from continuing operations rose 13% to $237.7 million, while underlying EBITDA climbed 47% to $20.3 million. Underlying profit before tax more than doubled to $15.7 million, operating cash flow reached $20.3 million and net cash stood at $46.5 million at 30 June.

The company attributed the improvement to broader activity across strata consolidation and mining services in Queensland and New South Wales, rather than a single contract or client. The midpoint of the FY27 EBITDA range implies a margin of about 9.6%, compared with 8.5% in FY26, reflecting the expected benefit of a larger revenue base and a changing mix of work.

Growth now brings execution and safety demands

Mastermyne expects its workforce to grow from 689 people at June to more than 1,000 by the end of January 2027 as the two major NSW projects ramp up. Management said frontline induction, supervision and mentoring would be a particular focus as new employees join the business. The company recorded no life-changing injuries in FY26 and reported lower incident severity, while extending its safety training to frontline supervisors and coordinators.

The balance sheet gives Mastermyne room to fund organic growth and consider acquisitions, with more than $70 million in largely undrawn working capital and asset finance facilities. The board has commissioned an external strategic review of surface mining services and is considering adjacent opportunities including drilling, other commodities and geographic expansion. In Queensland, Anglo American has named Mastermyne preferred tenderer for a potential three-year Moranbah North contract with a two-year option, but that arrangement remains subject to final contractisation and is not included in the order book.

Pipeline remains large after major awards convert

Mastermyne’s total pipeline stands at $1.3 billion, down from $1.5 billion at 30 June as opportunities converted into contracted work. The near-term component has nevertheless increased slightly to approximately $836 million, including the Moranbah North opportunity. The next test is whether the company can convert that pipeline while maintaining the safety, mobilisation discipline, margins and cash generation that its expanded operating footprint will require.

Get ASX:MYE news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The contract book now supports a materially larger FY27, but delivery on two major mobilisations and conversion of the remaining pipeline will determine how much of that opportunity becomes durable cash flow.

Questions in the middle?

  • Can Dendrobium and Tahmoor reach planned scale without diluting the targeted EBITDA margin or cash conversion?
  • When will the Moranbah North Letter of Intent become a binding contract, and what economics will the expanded scope carry?
  • Will the surface mining review produce an acquisition or organic expansion opportunity that meets Mastermyne’s return and risk criteria?

Sources

2